<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00490490</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-07479</org_study_id>
    <secondary_id>97437</secondary_id>
    <secondary_id>LYMNHL0046</secondary_id>
    <nct_id>NCT00490490</nct_id>
  </id_info>
  <brief_title>Study of Bexxar &lt;Tositumomab&gt; Combined With External Beam Radiation Therapy</brief_title>
  <official_title>Study of Bexxar &lt;Tositumomab&gt; Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the response rate of patients with relapsed or
      refractory low-grade or transformed low-grade, CD20-positive, B-cell non-Hodgkin's lymphoma
      to Iodine-131 (I-131) tositumomab (Bexxar) therapy plus local palliative radiation therapy
      (XRT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Response will be assessed on the basis of the presence or absence of measurable lesion ≥ 1.4
      x 1.4 cm (operationally defined as ≥ 2.0 cm2) by radiographic evaluation OR ≥ 1.0 cm in
      greatest diameter detected by palpation on physical exam
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low Accrual
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response (CR) Rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participants assessed for by the following Complete Response (CR) criteria
CR or Functional CR
No evidence of disease and symptoms
Any macroscopic nodules detected in any organs no longer present.
Any palpable lymph node is normal and greatest diameter is &lt; 1.0 cm.
The enlarged organs decreased in size and not palpable
The bone marrow biopsy and aspirate are negative for disease
Negative for disease by PET-scan (functional CR)
CR Unconfirmed (CRu) criteria
No evidence of disease and symptoms
Any lymph node mass &gt; 1.0 cm^2 diameter has regressed is size by more than 75%.
No macroscopic nodules in any organs
Any palpable lymph node is normal and greatest diameter is &lt; 1.0 cm.
The bone marrow biopsy and aspirate are negative for disease
The bone marrow biopsy may have increased number or size of lymphoid aggregates without cytologic or architectural atypia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>ORR is assessed as the sum of the overall rates of
CR confirmed by positron emission tomography (PET)
CR not confirmed by PET, and
Partial response (PR) negative for progression by PET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-Progression (TTP)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Tositumomab + XRT + KI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tositumomab + external beam radiotherapy (XRT) + potassium iodide (KI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexxar (tositumomab)</intervention_name>
    <description>Tositumomab is a CD20-directed radiotherapeutic (131-iodine) monoclonal antibody indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin's lymphoma who have progressed during or after rituximab therapy, including patients with rituximab-refractory non-Hodgkin's lymphoma. Tositumomab (standard regimen) will be administered at whole body exposure of 75 cGy.</description>
    <arm_group_label>Tositumomab + XRT + KI</arm_group_label>
    <other_name>131-iodine tositumomab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>External beam radiotherapy (XRT)</intervention_name>
    <description>Patient-specific XRT will begin within 24 hours of administration of the therapeutic dose of tositumomab. Subjects will receive local XRT to bulky sites of disease measuring at least 5 cm in at least one dimension. The size and number of fields to be treated will determined by the investigators, but will encompass the patient's most symptomatic/threatening site(s) of disease and not cumulatively include more than 25% of the active bone marrow. Subjects will be treated with the 2 x 2 Gy regimen (2 daily fractions of 2 Gy). Sites of disease previously-irradiated with 30 to 40 Gy will not be treated on this study.</description>
    <arm_group_label>Tositumomab + XRT + KI</arm_group_label>
    <other_name>Radiotherapy (RT)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium Iodide (KI)</intervention_name>
    <description>Potassium iodide (KI) will be administered as:
Saturated solution potassium iodide (SSKI) 4 drops orally 3-times-a-day,
Lugol's solution 20 drops orally 3-times-a-day, OR
KI tablets 130 mg orally once per day KI treatment will start at least 24 hours prior to tositumomab, and continue daily for 14 days following the last dose of tositumomab</description>
    <arm_group_label>Tositumomab + XRT + KI</arm_group_label>
    <other_name>Saturated Solution Potassium Iodide (SSKI)</other_name>
    <other_name>Lugol's solution</other_name>
    <other_name>Potassium iodide tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  Histologically confirmed low grade CD20+ B cell non-Hodgkin lymphoma (NHL) patients
             who have relapsed after chemotherapy or are chemotherapy resistant and have one or
             more sites of disease measuring more than 5 cm.

          -  The patients must have failed at least one chemotherapy regimen

          -  No anticancer treatment for three weeks prior to study initiation (six weeks if
             Rituximab, nitrosourea or Mitomycin C)

          -  Fully recovered from all toxicities associated with prior surgery, radiation,
             chemotherapy or immunotherapy

          -  An institutional review board- (IRB)-approved signed informed consent

          -  Age 19 years or older

          -  Expected survival of at least 6 months

          -  Prestudy Performance Status of 0, 1 or 2 according to the World Health Organization
             (WHO)

          -  Absolute neutrophil count (ANC) of at least 1,500/mm³

          -  Platelet count at least 100,000/mm³

          -  Hct &gt; 30%

          -  Hgb &gt; 9.0 gm

          -  Bilirubin ≤ 2.0

          -  Creatinine ≤ 2.0

          -  Bone marrow involvement with lymphoma less than 25% (bilateral bone marrow) within 6
             weeks of enrollment

          -  Acceptable birth control method for men and women

        EXCLUSION CRITERIA

          -  Disease progression within 3 months of last chemotherapy

          -  Prior myeloablative therapies with bone marrow transplantation or peripheral stem cell
             rescue

          -  Platelet count less than 100,000/mm³

          -  Hypocellular bone marrow (≤ 15% cellularity)

          -  Marked reduction in bone marrow precursors of one or more cell lines

          -  History of failed stem cell collection

          -  Prior treatment with fludarabine

          -  Prior radioimmunotherapy

          -  Presence of central nervous system (CNS) lymphoma

          -  HIV or AIDS-related lymphoma

          -  Evidence of myelodysplasia on bone marrow biopsy

          -  Abnormal bone marrow cytogenetics

          -  Patients who have received prior external beam radiation therapy to more than 25% of
             active bone marrow

          -  Patients who have received filgrastim

          -  Sargramostim therapy within 3 weeks prior to treatment

          -  Presence of human anti-mouse antibody (HAMA) reactivity in patients with prior
             exposure to murine antibodies or proteins

          -  Serious nonmalignant disease or infection, which, in the opinion of the investigator
             and/or sponsor, would compromise other protocol objectives

          -  Another primary malignancy (other than squamous cell and basal cell cancer of the
             skin, in situ carcinoma of the cervix, or treated prostate cancer with stable
             prostate-specific antigen, PSA) for which the patients has not been disease free for
             at least 3 years

          -  Major surgery, other than diagnostic surgery within 4 weeks

          -  Pleural effusion

          -  Pregnant

          -  Lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan J Knox</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2007</study_first_posted>
  <results_first_submitted>December 19, 2016</results_first_submitted>
  <results_first_submitted_qc>February 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2017</results_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Susan Knox</investigator_full_name>
    <investigator_title>Associate Professor of Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
    <mesh_term>Lugol's solution</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tositumomab + XRT + KI</title>
          <description>Tositumomab + external beam radiotherapy (XRT) + potassium iodide (KI)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Completed Assessment for CR</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Completed Assessment for TTP</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tositumomab + XRT + KI</title>
          <description>Tositumomab + external beam radiotherapy (XRT) + potassium iodide (KI)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology</title>
          <description>Participants were staged according to the Ann Arbor Staging Classification System, as below.
Stage / Characteristics
Involvement of 1 lymphatic region
Involvement of 2+ lymphatic regions on the same side of the diaphragm
Involvement of lymphatic regions on both sides of the diaphragm
Diffuse or disseminated involvement of 1+ extralymphatic organs</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Follicular Lymphoma, Grade 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Follicular Lymphoma, Grade 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Follicular Lymphoma, Grade 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Marginal Zone B-Cell Lymphoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Response (CR) Rate</title>
        <description>Participants assessed for by the following Complete Response (CR) criteria
CR or Functional CR
No evidence of disease and symptoms
Any macroscopic nodules detected in any organs no longer present.
Any palpable lymph node is normal and greatest diameter is &lt; 1.0 cm.
The enlarged organs decreased in size and not palpable
The bone marrow biopsy and aspirate are negative for disease
Negative for disease by PET-scan (functional CR)
CR Unconfirmed (CRu) criteria
No evidence of disease and symptoms
Any lymph node mass &gt; 1.0 cm^2 diameter has regressed is size by more than 75%.
No macroscopic nodules in any organs
Any palpable lymph node is normal and greatest diameter is &lt; 1.0 cm.
The bone marrow biopsy and aspirate are negative for disease
The bone marrow biopsy may have increased number or size of lymphoid aggregates without cytologic or architectural atypia</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tositumomab + XRT + KI</title>
            <description>Tositumomab + external beam radiotherapy (XRT) + potassium iodide (KI)</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response (CR) Rate</title>
          <description>Participants assessed for by the following Complete Response (CR) criteria
CR or Functional CR
No evidence of disease and symptoms
Any macroscopic nodules detected in any organs no longer present.
Any palpable lymph node is normal and greatest diameter is &lt; 1.0 cm.
The enlarged organs decreased in size and not palpable
The bone marrow biopsy and aspirate are negative for disease
Negative for disease by PET-scan (functional CR)
CR Unconfirmed (CRu) criteria
No evidence of disease and symptoms
Any lymph node mass &gt; 1.0 cm^2 diameter has regressed is size by more than 75%.
No macroscopic nodules in any organs
Any palpable lymph node is normal and greatest diameter is &lt; 1.0 cm.
The bone marrow biopsy and aspirate are negative for disease
The bone marrow biopsy may have increased number or size of lymphoid aggregates without cytologic or architectural atypia</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response (PR) or stable disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>ORR is assessed as the sum of the overall rates of
CR confirmed by positron emission tomography (PET)
CR not confirmed by PET, and
Partial response (PR) negative for progression by PET</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tositumomab + XRT + KI</title>
            <description>Tositumomab + external beam radiotherapy (XRT) + potassium iodide (KI)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>ORR is assessed as the sum of the overall rates of
CR confirmed by positron emission tomography (PET)
CR not confirmed by PET, and
Partial response (PR) negative for progression by PET</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All CR + PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-to-Progression (TTP)</title>
        <time_frame>2 years</time_frame>
        <population>One subject has not progressed (assessment not possible), and one subject has been lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Tositumomab + XRT + KI</title>
            <description>Tositumomab + external beam radiotherapy (XRT) + potassium iodide (KI)</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-Progression (TTP)</title>
          <population>One subject has not progressed (assessment not possible), and one subject has been lost to follow-up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>3 months</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 months</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>9 months</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>18 months</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>60 months</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tositumomab + XRT + KI</title>
          <description>Tositumomab + external beam radiotherapy (XRT) + potassium iodide (KI)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Thrombocytoperia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Leukocytopenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Equilibrium abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Stomach Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="14" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <description>Sweating, shock, shaking</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Body aches</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Finger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Mouth Sores</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Swollem Lymph Nodes</sub_title>
                <description>L grion, R collarbone, L neck and back</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Body Aches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Back spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain in Hip/Leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain at biopsy site (lower back)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>R Armpit Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain, side</sub_title>
                <description>Ribs hurt</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <description>In fingers/toes</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache, Chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="15" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Itchiness, hands and feet</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Itchiness, nose and mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan J. Knox, MD, Associate Professor of Radiation Oncology</name_or_title>
      <organization>Stanford University Medical Center</organization>
      <phone>(650) 725-2720</phone>
      <email>sknox@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

